☆ 4.7 Article

Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Microbiology

Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa

Christophe Le Terrier et al.

Summary: The impact of broad-spectrum beta-lactamases on the susceptibility to novel beta-lactamase/beta-lactamase inhibitor combinations was investigated in Pseudomonas aeruginosa and Escherichia coli. Cefepime-zidebactam showed low MICs due to zidebactam's intrinsic antibacterial activity. Cefepime-taniborbactam exhibited excellent activity against recombinant E. coli strains, including metallo-beta-lactamase producers, while aztreonam-avibactam remained the best therapeutic option against class B beta-lactamase-producing P. aeruginosa.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

添加到收藏夹

Article Immunology

Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial

Michael W. Dunne et al.

Summary: This study compared the clinical and microbiological responses of different treatment regimens in patients with complicated urinary tract infections, and the results showed that sulopenem was not superior to the comparator regimen.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Immunology

Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial

Michael W. Dunne et al.

Summary: This study demonstrates that sulopenem is an effective alternative for the treatment of urinary tract infections, with superiority in infections caused by resistant pathogens.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Infectious Diseases

In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases

Christophe Le Terrier et al.

Summary: The in vitro activity of aztreonam in combination with novel beta-lactamase inhibitors was evaluated against MDR MBL-producing Enterobacterales and Pseudomonas aeruginosa clinical isolates. The results showed that combinations including aztreonam and the inhibitors had significant activity against the isolates.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

添加到收藏夹

Article Infectious Diseases

NDM-9 resistance to taniborbactam

Christophe Le Terrier et al.

LANCET INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Chemistry, Organic

Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability

K. Raja Reddy et al.

BIOORGANIC & MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Immunology

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

Pranita D. Tamma et al.

Summary: This article provides updated guidance on the treatment of infections caused by ESBL-E, CRE, and DTR-P. aeruginosa. The guidance was developed by a panel of infectious diseases specialists and includes preferred and alternative treatment recommendations. The document emphasizes the importance of consulting with an infectious diseases specialist for the treatment of antimicrobial-resistant infections.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Medicine, General & Internal

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection

Paul B. Eckburg et al.

Summary: This study demonstrated the noninferiority of orally administered tebipenem pivoxil hydrobromide compared to intravenous ertapenem in the treatment of complicated urinary tract infection and acute pyelonephritis, with similar safety profiles.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Microbiology

Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018-2020 Global Surveillance Collection

James A. Karlowsky et al.

Summary: Ceftibuten-ledaborbactam is effective in inhibiting multidrug-resistant bacteria and has a high inhibitory rate against extended-spectrum β-lactamase-positive strains and strains resistant to various antibiotics.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Editorial Material Infectious Diseases

Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections

Balaji Veeraraghavan et al.

Summary: The treatment of urinary tract infections is complicated by multidrug-resistant pathogens expressing beta-lactamase. The emergence of oral antibiotics active against extended-spectrum beta-lactamase uropathogens is needed, with various drugs in clinical development. These new drugs have potential broad-spectrum coverage against resistant strains and will strengthen outpatient therapy.

INFECTIOUS DISEASES AND THERAPY (2021)

添加到收藏夹

Review Microbiology

NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings

Wenjing Wu et al.

CLINICAL MICROBIOLOGY REVIEWS (2019)

添加到收藏夹

Article Infectious Diseases

Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016

Andrew J. Denisuik et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)

添加到收藏夹

Article Chemistry, Medicinal

Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases

Alen Krajnc et al.

JOURNAL OF MEDICINAL CHEMISTRY (2019)

添加到收藏夹

Article Microbiology

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli

James A. Karlowsky et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017

Ian A. Critchley et al.

PLOS ONE (2019)

添加到收藏夹

Article Infectious Diseases

Tebipenem, the first oral carbapenem antibiotic

Akash Jain et al.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)

添加到收藏夹

Article Chemistry, Medicinal

Orally Absorbed Derivatives of the beta-Lactamase Inhibitor Avibactam. Design of Novel Prodrugs of Sulfate Containing Drugs

Eric M. Gordon et al.

JOURNAL OF MEDICINAL CHEMISTRY (2018)

添加到收藏夹

Article Infectious Diseases

Genomic epidemiology of global VIM-producing Enterobacteriaceae

Yasufumi Matsumura et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)

添加到收藏夹

Article Urology & Nephrology

Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013

Zafer Tandogdu et al.

WORLD JOURNAL OF UROLOGY (2016)

添加到收藏夹

Letter Immunology

The Need for Global Regulation of Antibiotics: The Case of a Generic Oral Penem

Simon Tiberi et al.

CLINICAL INFECTIOUS DISEASES (2016)

添加到收藏夹

Article Immunology

International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

Kalpana Gupta et al.

CLINICAL INFECTIOUS DISEASES (2011)

添加到收藏夹

Article Infectious Diseases

Faropelnem: review of a new oral penem

Kristen N. Schurek et al.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.